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Treat-to-Target Strategy in Osteoporosis
In addition to other chronic diseases such as hypertension, hypercholesterolemia, and diabetes, a
treat-to-target strategy was recently applied in rheumatoid arthritis and has now been discussed in
osteoporosis. An important goal of osteoporosis therapy is normal risk of hip fracture associated
with significant morbidity and mortality, but the anti-fracture efficacies of currently approved
drugs are limited (1, 2). Although fundamental methods to effectively prevent osteoporotic fracture
include pharmacological treatment of sarcopenia that results in improving bone fragility as well as
reducing fall risk, the present article focuses on anti-sclerostin antibodies such as romosozumab and
blosozumab, the investigational agents for osteoporosis, and provides new insights into their effects
from natural homeostatic system in the skeleton.
Alternative Drugs of Mechanical Strain-Related Stimulus
The human skeleton normally responds to the change in local mechanical environment at
each skeletal site to maintain resultant elastic deformation (strain) of bone; increased or
decreased bone strain would induce bone gain or loss, respectively (3–5). This mechanical
strain-related feedback control called the mechanostat (6, 7) plays a key role in the manage-
ment of osteoporosis; increased bone strength by an osteoporosis drug results in decreased
bone strain, indicating that the effect of osteoporosis therapy is limited by the mechanostat
(Figure 1) (5). Approaches to reduce the limitation include pharmacologically enhancing skeletal
response to mechanical stimulation (8), but this might not efficiently reduce the risk of fall-
related hip fracture because the skeleton is adapted to the mechanical environment resulting
from habitual physical activity but not to the unusual direction of mechanical force by falls.
Consequently, an ideal strategy is to develop an alternative agent of mechanical strain-related
stimulus (5).
One example would be investigational anti-sclerostin antibodies such as romosozumab and
blosozumab; experimental evidence has established that the production of sclerostin secreted by
osteocytes is increased by skeletal disuse and decreased by skeletal loading (9, 10). In addition,
bone formation induced by intermittent treatment with parathyroid hormone is associated with the
inhibition of sclerostin (11), suggesting that teriparatide could partly have a similar effect. There is,
however, an obvious difference between the effects of anti-sclerostin antibodies and teriparatide, if
injected daily (8), on bone remodeling; remodeling-based, coupled bone resorption and formation
are significantly promoted by the latter, but not by the former.
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FIGURE 1 |Mechanical strain-related feedback control of bone
strength. A long arrow indicates the effect of osteoporosis therapy that
increases bone strength and thus decreases bone strain from physical
activity, and short arrows indicate the negative feedback control of bone
strength that returns bone strain to its pre-treatment level (5).
Modeling-Based Effects of Anti-Sclerostin
Antibodies
In contrast to bone remodeling, modeling-based bone formation
and resorption are not coupled, and mechanical stimulation is
a natural uncoupling factor that stimulates bone formation and
inhibits bone resorption; experimental data in skeletally mature
animals (12, 13) show that strong suppression of bone resorption
by risedronate or denosumab does not impair modeling-based
bone formation induced by artificial mechanical loading or habit-
ual physical activity. In agreement with the above suggestion that
investigational anti-sclerostin antibodies such as romosozumab
and blosozumab are alternative drugs of mechanical strain-
related stimulus, an experiment using male cynomolgus monkeys
found a marked increase in modeling-based bone formation by
romosozumab (14) and phase 2 clinical studies in postmenopausal
women confirmed that both romosozumab and blosozumab treat-
ments rapidly induced an increase in bone formation and a
decrease in bone resorption (15, 16).
Optimal Doses of Anti-Sclerostin
Antibodies
In postmenopausal women with low areal bone mineral den-
sity (BMD), romosozumab and blosozumab treatments for
1 year increased areal BMD at the lumbar spine and hip dose-
dependently; mean changes from baseline in areal BMD at the
lumbar spine, total hip and femoral neck by romosozumab
[placebo vs. highest dose (210mg every 1month)] were  0.1 vs.
11.3%,  0.7 vs. 4.1%, and  1.1 vs. 3.7%, respectively, while those
by blosozumab [placebo vs. highest dose (270mg every 2weeks)]
were 1.6 vs. 17.7%, 0.7 vs. 6.7%, and 0.6 vs. 6.3%, respectively
(15, 16). Notably, however, areal BMD at the one-third radius
was not changed by the highest dose of romosozumab ( 0.9
vs.  1.2%, respectively) and non-significantly increased only by
the highest dose of blosozumab ( 1.4 vs. 0.9%, respectively)
(15, 16).
The effects of anti-sclerostin antibodies at the radius appear
to reflect the fact that forearm is not exposed to high levels of
mechanical strain under normal physical activity. Experimental
evidence that the production of sclerostin secreted by osteocytes
is increased by skeletal disuse and decreased by skeletal loading
(9, 10) suggests that the levels of sclerostin expression in non-
weight-bearing bones such as the radius could be higher than
those in weight-bearing bones such as the lumbar spine and
hip. Consequently, it would be possible to speculate that even
highest doses of romosozumab and blosozumab selected in phase
2 clinical studies were not enough for the radius. Indeed, the
strongest effects on areal BMD at the lumbar spine and hip
were achieved with the highest dose of blosozumab and only
this regimen resulted in a trend of increase in areal BMD at
the radius (15, 16); further higher doses of blosozumab might
increase areal BMD at the radius dose-dependently. Several lines
of evidence to support this hypothesis include (i) patients with
sclerosteosis due to deficiency of sclerostin have higher areal
BMD at the radius as well as the lumbar spine and hip (17)
and (ii) appropriate doses of anti-sclerostin antibodies effectively
increase bone mass in animals with skeletal disuse or unloading
(18, 19).
If the above logic is correct, the highest doses of romosozumab
(210mg every 1month) and blosozumab (270mg every 2weeks)
are unlikely to cause unwanted bony overgrowth at non-weight-
bearing sites such as the face and skull in postmenopausal women
with osteoporosis. In contrast, however, further higher doses of
these drugs would be required to improve skeletal fragility in
patients with reduced physical activity; one useful indicator to
determine optimal doses of anti-sclerostin antibodies could be
areal BMD at the radius.
Limitation of Treatment with
Anti-Sclerostin Antibodies
Both romosozumab and blosozumab treatments in postmeno-
pausal women with low areal BMD showed that marked changes
in circulating bone formation and resorption markers returned
to the pre-treatment levels within a year despite the continued
treatments (15, 16). The existence of other mechanotransduc-
tion pathways independent of sclerostin (20) indicates that treat-
ment with an anti-sclerostin antibody cannot escape from the
mechanostat-related limitation of osteoporosis therapy (5).
The relation between circulating sclerostin and bone mass
would support this theory. Sclerostin-related high bone mass in
patients with sclerosteosis or van Buchem disease and heterozy-
gous carriers of these diseases is linked to lower levels of circu-
lating sclerostin (21, 22), while circulating sclerostin and bone
mass in normal women and men have a positive correlation (23–
25). This discrepancy suggests that higher bone mass associated
with other mechanotransduction pathways independent of scle-
rostin would cause lower mechanical strain in the skeleton and
thus could result in compensatory higher sclerostin production
according to the mechanostat, although the positive correlation
between circulating sclerostin and bonemass is also influenced by
the fact that higher bone mass results in more osteocytes, which
are the main source of sclerostin (26).
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Withdrawal of Treatment with
Anti-Sclerostin Antibodies
Results of 1-year post-treatment follow-up after 1-year treatment
with blosozumab were recently reported in the phase 2 clini-
cal trial of postmenopausal women with low areal BMD. Mean
changes from baseline in areal BMD at the lumbar spine, total
hip, and femoral neck by the highest dose (270mg every 2weeks)
of blosozumab (1-year treatment vs. 1-year treatment plus 1-year
follow-up without treatment) were 17.7 vs. 6.9%, 6.7 vs. 3.9%, and
6.3 vs. 5.3%, respectively (27).
The mechanostat indicates that bone strength returns to base-
line after the withdrawal of treatment (5) and the speed of this
reverse change depends on the drug (28–30). The above site-
specific difference in the reduction of areal BMD could partly
result from less mechanical loading at the lumbar spine, possibly
associated with higher sclerostin production (9, 10). Treatment
with an anti-sclerostin antibody can reinforce the fragile skeleton
by non-site-specific bone apposition, while its discontinuation
would result in mechanical strain-related, site-specific bone loss.
Local bone strain from normal physical activity is lower in the
inner compartments, suggesting that bone loss caused by the
mechanostat-related negative feedback is higher at the trabecular
and endosteal surfaces. In contrast, newly formed bone at the
periosteal surface through modeling-based apposition might not
be resorbed because of a lack of efficient bone resorption in this
region.
Conclusion
Anti-sclerostin antibodies such as romosozumab and blosozumab
are the alternative drugs ofmechanical strain-related stimulus that
can overcome the mechanostat-related limitation of osteoporosis
therapy (Figure 1) (5). It is expected that these agents will make a
treat-to-target strategy in osteoporosis possible in the near future.
Further studies are desired to investigate their optimal doses,
especially depending on the levels of habitual physical activity, as
well as appropriate duration of the treatments.
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